Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal Carcinoma

Cancer

Volumn 113, Issue 6, 2008, Pages 1332-1337

  Leong, Swan Swan ^a   Wee, Joseph ^a   Rajan, Sandeep ^a   Toh, Chee Keong ^a   Lim, Wan Teck ^a   Hee, Siew Wan ^a   Tay, Miah Hiang ^a   Poon, Donald ^a   Tan, Eng Huat ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Chemotherapy; Induction; Maintenance; Nasopharyngeal carcinoma

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; ONDANSETRON; PACLITAXEL; RANITIDINE;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NASOPHARYNX CARCINOMA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TRANSAMINITIS; TREATMENT RESPONSE;

EID: 53149111132     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23687     Document Type: Article

References (30)

1. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310-1317.
2. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against Cancer stage III and IV nasopharyngeal cancer of endemic variety. J Clin Oncol. 2005;23:6730-6738.
3. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97:536-539.
4. Zhang L, Zhao C, Peng PJ, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol. 2005;23:8461-8468.
5. Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic carcinoma. Ann Oncol. 1994;5:87-89.
6. Tan EH, Khoo KS, Wee J, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999;10:235-237.
7. Yeo W, Leung TW, Chan AT, et al. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer. 1998;34:2027-2031.
8. Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: a report of a phase II study. Ann Oncol. 2002;13:1252-1258.
9. Greco FA, Spigel DR, Kuzur ME, et al. Paclitaxel/carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase III/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007;8:483-487.
10. Liu FS, Ho ES, Hung MJ, Hwang SF, Lu CH, Ke YM. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan. Gynecol Oncol. 2004;94:393-397.
11. Leong SS, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase II trial using a triplet combination. Cancer. 2005; 103:569-575.
12. Pignata S, Breda E, Scambia G, et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol. 2008;66:229-236.
13. Ku GY, Ilson DH, Schwartz LH, et al. Phase II trial of sequential paclitaxel and 1h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2008 Feb. 13 (Epub].
14. Homesley HD, Meltzer NP, Nieves L, Vaccarello L, Lowendowski GS, Elbendary AA. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. Int J Clin Oncol. 2008;13:62-65.
15. Linch M, Stavridi F, Hook J, Barbachano Y, Gore M, Kaye SB. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecol Oncol. 2008;109:27-32.
16. Belani CP, Ranalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:468-473.
17. Hong RL, Sheen TS, Ko JY, Hsu MM, Wang CC, Ting LL. Induction with mitomycin, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. Br J Cancer. 1999;80:1962-1967.
18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85:365-376.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:201-216.
20. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143-151.
21. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley, on Behalf of the EORTC Quality of Life Group: The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels, Belgium: European Organisation for Research and Treatment of Cancer; 2001.
22. Chi KH, Chan WK, Cooper DL, Yen SH, Lin CZ, Chen KY. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. Cancer. 1994;73:247-252.
23. Chi KH, Chan WK, Shu CH, et al. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer. 1995; 76:2186-2192.
24. Siu LL, Czaykowski PM, Tannock IF. Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol. 1998;16:2514-2521.
25. Hasbini A, Mahjoubi R, Fandi A, et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of the nasopharyngeal type. Ann Oncol. 1999; 10:421-425.
26. Taamma A, Fandi A, Azli N, et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer. 1999;86:1101-1108.
27. Fandi A, Taamma A, Azli N, et al. Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type. Head Neck. 1997;19:41-47.
28. Chua DT, Kwong DL, Sham JS, Au GK, Choy D. A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer. 2000;36:736-741.
29. Poon D, Chowbay B, Cheung YB, Leong SS, Tan EH. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer. 2005;103: 576-581.
30. Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol. 2003;39:361-366.